Introduction
Interim results from a Phase 2 study evaluating a dose of 1.5 mg/kg of dusquetide as a treatment for severe oral mucositis (SOM) in head and neck cancer (HNC) patients receiving chemoradiation therapy (CRT) demonstrated a 50% decrease in the median duration of severe oral mucositis (SOM) in patients receiving at least 55 Gy irradiation [1] . Patients at higher risk for SOM showed even greater improvements (67%) relative to placebo, particularly in the treatment group receiving the 1.5 mg/kg dose of dusquetide [1] . Over this same treatment period, an increased number of patient classified as having a "complete tumor response" using the RECIST 1.1 tumor status system and a decreased "non-fungal" (i.e. bacterial) infection rate were also observed. Long term follow-up visits were conducted on these same patients for 12 months after the completion of CRT, with the last visits occurring in the fall of 2016.
There are no treatments for SOM approved by the U.S. Food and Drug Administration (FDA) for use in HNC or other cancers with solid tissue tumors. In the case of hematologic tumors, there is only one approved therapy (palifermin), a tissue growth factor which presumably encourages the growth and regrowth of the oral mucosa tissue. Palifermin is specifically approved for use in patients receiving hematopoietic stem cell support for a myelotoxic therapy of a hematologic cancer which lack the receptor for the growth factor [2, 3] . Due to its function as a tissue growth factor, palifermin is associated with a potential risk of stimulating/encouraging solid tumor proliferation [4] [5] [6] and is therefore contra-indicated in the case of solid tumors, all of which express the growth factor receptor. Other treatment approaches are under development [7, 8] but none have been approved and the risk of interfering with tumor treatment or encouraging tumor growth remains a primary concern [9] .
Innate immunity is believed to play a key role in the pathogenesis of oral mucositis [10] [11] [12] [13] and indeed the efficacy of dusquetide as an Innate Defense Regulator supports this understanding [14, 15, 1] . Dusquetide (SGX942) is a first-in-class Innate Defense Regulator (IDR) that modulates the innate immune response downstream of most innate immune receptors, acting at a key adaptor protein known as p62 or sequestosome-1 [14] . Dusquetide modulates innate immune signaling from a pro-inflammatory, pro-macrophage response to an anti-inflammatory and increased pro-macrophage response. This response leads to decreased inflammation, increased bacterial clearance and increased tissue healing [14] [15] [16] . Importantly, dusquetide is not an antiapoptotic or anti-necroptosis agent and cannot directly mitigate the damage done by CRT to the tumor [1] .
Although direct interference with tumor therapy is unlikely, and indeed demonstrated not to occur preclinically [1] , there are other potential ancillary effects of p62 interactions on tumor biology [17] . Specifically, p62 is a ubiquitous protein that is present in most cells, including aberrant tumor cells, and, through its role in autophagy, has been shown to impact tumorigenesis [18] . Thus, p62 is believed to be important in the tumorigenesis of MCF-7 (breast cancer cell line) where autophagy is otherwise inhibited [19, 20] . Again, a xenograft study with MCF-7 cells not only demonstrated a lack of interference with CRT but also demonstrated a lack of tumor enhancement with SGX942 treatment. In fact, reduction in tumor volume was observed preclinically with SGX942 treatment [1] .
Innate immunity also plays a role in establishing the microenvironment around a tumor. For example, p62 has been directly implicated in facilitating the stromal cell microenvironment in multiple myeloma via a mechanism involving increased IL-6 signaling [21, 22] .
To address the remote possibility that dusquetide may protect and/ or enhance tumor growth, tumor resolution was monitored in the context of multiple myeloma cell growth in the presence of stromal cells and throughout a recent Phase 2 HNC study, both immediately after treatment and throughout a 12-month follow-up period. Similarly, overall survival of these HNC patients was also monitored through this same period.
Results and discussion
Dusquetide was not expected to negatively impact the stromal microenvironment of multiple myeloma cells, since this signaling has been reported to rely on IL-6 signaling [21] and dusquetide has been shown to significantly reduce IL-6 [15] . Nonetheless, a co-culture system with human multiple myeloma cells was previously investigated and demonstrated that when dusquetide was pre-incubated with stromal cells, those same stromal cells provided reduced support for multiple myeloma cell growth (Fig. 1) .
As reported previously [1] , dusquetide (SGX942) reduced the median duration of SOM between initiation of CRT and the 1-month follow-up visit in a 111-patient double-blind placebo-controlled Phase 2 clinical trial of OM in HNC patients. In the patient population receiving at least 55 Gy irradiation, this reduction was 50% (18 days vs. 9 days in the placebo and SGX942 1.5 mg/kg treatment groups respectively, p = 0.099). In higher risk subpopulations, this reduction improved to 67% (30 days vs. 10 days in the placebo and SGX942 1.5 mg/kg group respectively [p = 0.040] in those patients receiving the highest doses of cisplatin chemotherapy). Ancillary measures during this initial window between initiation of CRT and the 1-month follow-up visit also demonstrated a decreased rate of non-fungal infection and an increased rate of "complete response" in the tumor assessments at the 1-month follow-up visit. The anti-infective and anti-inflammatory/tissue healing aspects of dusquetide were expected on the basis of previous preclinical work [15, 1] .
The one-year mortality rate in the placebo group was 81% (Fig. 2) , consistent with the Surveillance, Epidemiology, and End Results statistics of approximately 80% survival for patients with tumors of the oral cavity, depending on tumor location [23] . In the dusquetide treatment groups, mortality was significantly lower. Using the pre-determined cutoff of p < 0.1 for statistical significance in this exploratory study yielded statistically significant improvement in survival using Kaplan-Meier analysis (Fig. 2) , compared to placebo. This decreased mortality was primarily observed in the follow-up period (after the 1-month follow-up visit), suggesting it was not related to the decreased infection rate also observed in the dusquetide treated groups in this study prior to the 1-month follow up visit. While the underlying cause of the decreased mortality is unknown, these results certainly support the contention that SGX942 was safe and well-tolerated, without any identifiable negative side-effects in this patient population.
We previously reported a trend towards improved tumor resolution at 1-month post CRT using the RECIST v 1.1 criteria [24] . While it was not previously possible to ascertain if this improvement was transient or enduring, monitoring throughout the 12-month follow-up window demonstrated that the effect was in fact enduring (Table 1) . Moreover, the The detailed study design is described in [1] . Survival was monitored for the 12 months following completion of chemoradiation therapy.
patients in the placebo group continued to improve, eventually having a response rate more similar to the 1.5 mg/kg dusquetide treated group (Table 1) . These results may indicate that dusquetide accelerated the tumor resolution. Given the size of this initial Phase 2 trial, it is impossible to ascertain if this improvement was due to increased compliance with CRT therapy or due to a direct effect of dusquetide on the tumor and its microenvironment. Given the known biology of p62 and the previously reported preclinical findings, it is possible that dusquetide had a direct anti-tumor effect in addition to reducing the duration of SOM. These results demonstrate that not only does dusquetide reduce the duration of a debilitating and burdensome side effect of most cancer treatment regimens, but that it could be associated with significant ancillary benefits including decreased infection rates and accelerated tumor resolution.
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